Here, we developed an in‐house ELISA with three p16‐derived linear peptide antigens to examine plasma anti‐p16 antibody levels in patients with non‐small cell lung cancer (NSCLC). The gene discussed is CDKN2A; the disease is non-small cell lung carcinoma.